



DFIN CASE STUDY

How we helped a biotech company streamline their SEC filing and drive efficiencies.

NEW ActiveDisclosureSM
by DFIN

virax  biolabs

CORPORATE SNAPSHOT

Virax Biolabs is an innovative biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases.

Their mission is the global provision of high-quality diagnostic kits, particularly T-Cell tests, which predict an individual's immune response to significant viral threats.



**Founded in
2013**



**IPO in July
2022**



**Foreign
Issuer**

CHALLENGE

Accurate, on time SEC filing with minimal staff

Virax Biolabs is in the early stage of company formation and growth. The company was challenged with several SEC filings at an early stage compared to an established company.

With a small accounting team placed all over the world, Virax Biolabs was seeking an opportunity to streamline their process and wanted a more efficient, collaborative solution that would improve productivity in their department.



SOLUTION

New ActiveDisclosure is Faster, More Intuitive, and Collaborative

Virax Biolabs needed an affordable, intuitive solution that could help their company comply with SEC filing requirements quickly and efficiently with minimal staff. New ActiveDisclosure handled the heavy-lifting of financial reporting and SEC filing requirements, saving the team time and money. The combination of purpose-built features, including collaboration tools and seamless XBRL review, helped our client drive efficiencies and allowed them to confidently submit their filings.



BOOSTS COLLABORATION

Employees in multiple locales draft in tandem



INCREASES ACCURACY

100% error-free submissions



SAVES TIME

Secure, intuitive tools for ease of use and speed to filing

In our opinion, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly, ↑

010-Cover

Josh Duncan Today - 11:16 AM

030-Balance Sheets

Stan Smith Today - 9:55 AM

040-Statements of Operations

Amy Flannery Today - 12:29 AM

Do you want to replace this workbook?

Original	Updated
11 Tables	11 Tables
105 Items	105 Items



Our consolidated financial statements as of September 30, 2020, and the results of operations for the three months ended March 31, 2020, and for 2020. Operating results for the three months ended March 31, 2020, and for the three months ended September 30, 2020, are necessarily indicative of what may be expected for the full year 2020.

Assets

Current Assets:

Cash

Accounts receivable

Prepaid expenses

Total current assets

Building and land

“

ActiveDisclosure seamlessly combines all aspects of the SEC reporting process under one simplified platform. The easy integration with Microsoft Office products enables all levels of the accounting and legal departments to confidently navigate drafting, editing and linking Excel tables that results in an error-free end product ready for filing. Bringing the filing function in-house creates an umbrella of controls and alleviates downtime when it comes to reviews and collaborations.


JASON DAVIS

CFO



Streamline SEC filing and optimize efficiencies.

The new ActiveDisclosure is purpose-built and affordable with a robust set of advanced capabilities. Seamless integration with data sources (e.g., Excel) saves time, reduces errors, and lowers costs. Unsurpassed security ensures peace of mind.




USER-FRIENDLY EXPERIENCE

Delivers instant access to projects for rapid task completion



INTELLIGENT iXBRL TAGGING

Lowers the complexity of making filings compliant



REPORTS AND DATA LINKING

Updates reports automatically when source data changes



HEALTH CHECKS AND VALIDATIONS

Ensures key filing requirements are not missed



FORTIFIED SECURITY AND PRIVACY

Protects clients and data with SOC 2 Type II audits



Get in touch

[DFINsolutions.com](https://www.dfinsolutions.com)

35 West Wacker Drive
Chicago, Illinois 60601
United States
+1 866 319 7064

APAC: +852 2522 3803
EMEA: +44 203 047 6100
LATAM: +55 11 3031 6327